Bladder cancer is a prevalent and life-threatening malignancy that poses significant challenges in diagnostics and therapeutics. At Protheragen, our team of experienced biological specialists understands that choosing the right animal model is crucial for the success of any bladder cancer research project. We offer comprehensive model development services, taking into account the specific research objectives of our clients.
Introduction to Bladder Cancer (BLC) Animal Models
Bladder cancer, a leading global health concern, necessitates robust preclinical models for understanding tumor biology, evaluating therapies, and predicting clinical outcomes. Animal models are indispensable in bladder cancer research, offering insights into disease progression, molecular mechanisms, and therapeutic responses. They bridge the gap between basic science and clinical application, enabling the systematic investigation of bladder cancer pathophysiology. These models facilitate the identification of potential biomarkers and the testing of novel therapeutic agents, contributing significantly to the development of innovative therapeutic strategies.
Fig.1 Porcine bladder cancer models. (Segatto N. V.,
et al., 2021)
Types of Bladder Cancer (BLC) Animal Models
- Chemical-Induced Models
N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) is a potent bladder carcinogen widely used to induce bladder cancer in rodents. BBN administration results in tumors with histopathological features closely resembling human bladder cancer, making it a valuable tool for carcinogenesis studies and drug efficacy evaluation. For instance, research has demonstrated that BBN-induced models can be used to assess the chemopreventive effects of various compounds, providing critical data for the development of preventive strategies.
- Transgenic and Knockout Models
Engineered to express or lack specific genes associated with bladder cancer, transgenic and knockout models offer a powerful approach to study gene function and carcinogenesis. For example, models overexpressing oncogenes like HRAS or deficient in tumor suppressor genes such as TP53 can spontaneously develop bladder tumors. These models have been instrumental in elucidating the molecular pathways driving bladder cancer progression and in identifying potential therapeutic targets.
- Xenograft Models
Human bladder cancer cell lines xenografted into immunocompromised mice serve as a mainstay for evaluating anti-tumor therapies. Subcutaneous xenografts provide a rapid and straightforward method for assessing tumor growth inhibition, while orthotopic models, where tumor cells are implanted into the bladder, better replicate the tumor microenvironment and clinical presentation. Studies utilizing these models have been pivotal in advancing our understanding of therapeutic resistance and in the preclinical testing of novel agents like immune checkpoint inhibitors.
- Syngeneic Models
Syngeneic models, which involve the implantation of tumor cells into immunocompetent hosts, are gaining prominence in immuno-oncology research. Models such as the MB49 murine bladder cancer cell line transplanted into C57BL/6 mice allow for the study of immune-tumor interactions and the efficacy of immunotherapies. These models have been crucial in investigating the role of the immune microenvironment in bladder cancer and in developing immunotherapeutic strategies.
Our Services
Protheragen, a leader in preclinical research services, provides cutting-edge bladder cancer animal model development tailored to meet diverse research objectives. With a team of seasoned biological specialists and state-of-the-art facilities, Protheragen offers comprehensive services from model customization to validation and beyond.
In Situ Carcinogen-Induced Bladder Cancer Models
Protheragen excels in developing carcinogen-induced bladder cancer models using well-established carcinogens such as nitrofurantoin, thiazole formamide (FANFT), N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), and N-methyl-N-nitrosourea (MNU).
FANFT-Induced Models
FANFT is a nitrofuran derivative that acts as an indirect carcinogen. It is typically administered orally, and its carcinogenic effects become evident after an induction period of over 8 months. This model is highly effective, with a tumor formation rate approaching 100% in experimental animals. For instance, we can use female Fisher344 rats and provide them with drinking water containing 0.05% BBN for 8 weeks to induce bladder cancer. This model is particularly useful for studying the long-term effects of carcinogens and the development of bladder cancer over time.
BBN-Induced Models
BBN is a highly potent carcinogen that can be administered either orally or via intravesical instillation, offering researchers a versatile experimental approach. It typically induces bladder cancer within 5 to 8 months, which is significantly faster than FANFT, making it a more efficient choice for studies requiring rapid tumor induction. BBN’s ability to act both as a direct and indirect carcinogen adds to its flexibility in experimental design. Our team can tailor the administration route and duration to meet specific research needs, ensuring that the model is perfectly aligned with the study objectives.
MNU-Induced Models
MNU, a nitrosamine compound, is widely recognized for its ability to rapidly induce bladder cancer. Similar to BBN, MNU can be administered either orally or through intravesical instillation, offering researchers flexibility in their experimental designs. This model is particularly useful for studying the early stages of bladder cancer development, as it allows for the observation of initial cellular changes and the effects of short-term carcinogenic exposure. Researchers can gain valuable insights into the early mechanisms of cancer initiation, making the MNU model an important tool in bladder cancer
Orthotopic Bladder Cancer Models
Protheragen offers robust orthotopic bladder cancer models, where tumor cells are directly implanted into the bladder. This method closely replicates the human disease, providing a highly relevant preclinical model for studying bladder cancer biology and evaluating therapeutic efficacy.
Orthotopic Transplantation
Our team uses advanced techniques to implant bladder cancer cells directly into the bladder. For example, we employ a novel experimental device to insert a catheter into the bladder of experimental mice. The device cuts and disrupts the normal bladder mucosa, creating a suitable environment for the implantation of human bladder cancer cell lines such as EJ. This method ensures the accurate and reproducible establishment of orthotopic bladder tumors, making it an ideal choice for preclinical drug testing and efficacy studies.
Heterotopic Bladder Cancer Models
Protheragen also offers heterotopic bladder cancer models, where tumor cells are implanted into sites other than the bladder, such as subcutaneous tissues, the peritoneal cavity, or veins. These models are valuable for initial drug screening and studying tumor growth and metastasis.
Heterotopic Implantation
In our heterotopic models, tumor cells or tumor tissue fragments are implanted into various sites in experimental animals, such as the subcutaneous space (commonly the flank or hind limb), the peritoneal cavity, or veins. This method allows for the rapid establishment of tumors and provides a flexible platform for studying tumor growth dynamics and metastatic potential. While these models do not fully replicate the bladder microenvironment, they offer significant advantages for initial drug efficacy studies and the investigation of metastatic mechanisms.
Cell Line-Derived Xenograft (CDX) Models
| Cell Line |
Detailed Description |
Organism |
Sales Status |
| RT112-Luc |
Luciferase-labeled RT112 cell line |
Human |
Construction |
| J82 |
The malignant human urothelial cell line (J82) was derived from the bladder. |
Human |
Validation of tumorigenic capacity completed |
| MB-49 |
Mouse bladder cancer cell line |
Mouse |
Validation of tumorigenic capacity |
| RT112 |
Human bladder cancer cell line |
Human |
Validation of tumorigenic capacity |
| RT4 |
Human bladder transitional cell papilloma cell line |
Human |
Validation of tumorigenic capacity |
| SW780 |
The SW780 cell line is a cell line exhibiting epithelial morphology that was isolated from the urinary bladder of a patient with transitional cell carcinoma. |
Human |
Validation of tumorigenic capacity completed |
| T24 |
Human bladder cancer cell line |
Human |
Validation of tumorigenic capacity |
| UM-UC-3 |
human bladder cancer cell line |
Human |
Validation of tumorigenic capacity |
Case Study
Subcutaneous bladder cancer xenograft animal model:
- Mouse information: CB17 SCID
- Cell line: HT-1376
Fig.2 Tumor growth and body weight changes in the subcutaneous transplantation model of HT-1376 cells.
Protheragen excels in creating bespoke animal models that mirror the complexity of human bladder cancer. Whether it's replicating specific genetic mutations, tumor stages, or microenvironmental conditions, our expertise ensures models that closely mimic clinical scenarios. This precision is vital for generating reliable preclinical data that can accelerate drug discovery and development. If you are interested in our services, please feel free to contact us.
Reference
- Segatto, Natalia Vieira, et al. "Perspective: humanized pig models of bladder cancer." Frontiers in Molecular Biosciences 8 (2021): 681044.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
